MCM
BMRN icon

MV Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

MV Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8
Closed -$440 – 1078
2025
Q2 		$440 Sell
8
-2
-20% -$118 ﹤0.01% 866
2025
Q1 		$707 Sell
10
-60
-86% -$4.04K ﹤0.01% 788
2024
Q4 		$4.6K Buy
70
+62
+775% +$4.15K ﹤0.01% 615
2024
Q3 		$563 Sell
8
-2
-20% -$167 ﹤0.01% 796
2024
Q2 		$824 Buy
10
+5
+100% +$416 ﹤0.01% 705
2024
Q1 		$437 Buy
5
+1
+25% +$90 ﹤0.01% 710
2023
Q4 		$386 Buy
+4
New +$354 ﹤0.01% 690
2018
Q2 		– Sell
-500
Closed -$41K – 356
2018
Q1 		$41K Buy
+500
New +$42.9K 0.01% 168

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

MV Capital Management's BMRN Position: Q3 2025 in Review

MV Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 8 shares — an estimated $440 sold.

MV Capital Management first reported a position in BMRN in Q1 2018 and held it in 8 quarters. The position peaked at $41K in Q1 2018. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • MV Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • MV Capital Management sold 8 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $440.
  • MV Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 8 quarters.
  • MV Capital Management's BioMarin Pharmaceuticals position peaked at $41K in Q1 2018.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on MV Capital Management's 13F filing for Q3 2025, filed 23 Feb 2026.